Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
RXII's Cash to Debt is ranked higher than
82% of the 1276 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. RXII: No Debt )
RXII' s 10-Year Cash to Debt Range
Min: 0.35   Max: No Debt
Current: No Debt

Equity to Asset 0.43
RXII's Equity to Asset is ranked higher than
60% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. RXII: 0.43 )
RXII' s 10-Year Equity to Asset Range
Min: -1.04   Max: 0.52
Current: 0.43

-1.04
0.52
Interest Coverage No Debt
RXII's Interest Coverage is ranked higher than
72% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. RXII: No Debt )
RXII' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: -5.83
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -10509.30
RXII's Operating margin (%) is ranked higher than
51% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -85.54 vs. RXII: -10509.30 )
RXII' s 10-Year Operating margin (%) Range
Min: -13376.29   Max: -5250.38
Current: -10509.3

-13376.29
-5250.38
Net-margin (%) -10469.77
RXII's Net-margin (%) is ranked higher than
51% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. RXII: -10469.77 )
RXII' s 10-Year Net-margin (%) Range
Min: -13278.35   Max: -5244.36
Current: -10469.77

-13278.35
-5244.36
ROE (%) -152.64
RXII's ROE (%) is ranked higher than
54% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -32.57 vs. RXII: -152.64 )
RXII' s 10-Year ROE (%) Range
Min: 0   Max: 0
Current: -152.64

ROA (%) -67.13
RXII's ROA (%) is ranked higher than
60% of the 1282 Companies
in the Global Biotechnology industry.

( Industry Median: -26.11 vs. RXII: -67.13 )
RXII' s 10-Year ROA (%) Range
Min: -353.55   Max: -203.85
Current: -67.13

-353.55
-203.85
ROC (Joel Greenblatt) (%) -5260.77
RXII's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 1245 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. RXII: -5260.77 )
RXII' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -13106.06   Max: -11172.8
Current: -5260.77

-13106.06
-11172.8
» RXII's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with RXII

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.43
RXII's P/B is ranked higher than
70% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 6.46 vs. RXII: 5.43 )
RXII' s 10-Year P/B Range
Min: 4.99   Max: 50
Current: 5.43

4.99
50
EV-to-EBIT -0.86
RXII's EV-to-EBIT is ranked lower than
51% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RXII: -0.86 )
RXII' s 10-Year EV-to-EBIT Range
Min: -7.7   Max: -0.3
Current: -0.86

-7.7
-0.3
Current Ratio 9.25
RXII's Current Ratio is ranked higher than
86% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. RXII: 9.25 )
RXII' s 10-Year Current Ratio Range
Min: 0.48   Max: 11.98
Current: 9.25

0.48
11.98
Quick Ratio 9.25
RXII's Quick Ratio is ranked higher than
86% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. RXII: 9.25 )
RXII' s 10-Year Quick Ratio Range
Min: 0.48   Max: 11.98
Current: 9.25

0.48
11.98

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.00
RXII's Price/Net Cash is ranked higher than
91% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 87.00 vs. RXII: 4.00 )
RXII' s 10-Year Price/Net Cash Range
Min: 6.14   Max: 11.92
Current: 4

6.14
11.92
Price/Net Current Asset Value 5.84
RXII's Price/Net Current Asset Value is ranked higher than
81% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 28.08 vs. RXII: 5.84 )
RXII' s 10-Year Price/Net Current Asset Value Range
Min: 8.33   Max: 38.82
Current: 5.84

8.33
38.82
Price/Tangible Book 5.43
RXII's Price/Tangible Book is ranked higher than
76% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 9.40 vs. RXII: 5.43 )
RXII' s 10-Year Price/Tangible Book Range
Min: 8.14   Max: 35.58
Current: 5.43

8.14
35.58
Earnings Yield (Greenblatt) -116.30
RXII's Earnings Yield (Greenblatt) is ranked lower than
58% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. RXII: -116.30 )
RXII' s 10-Year Earnings Yield (Greenblatt) Range
Min: -84   Max: 0
Current: -116.3

-84
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:44R.Germany,
RXi Pharmaceuticals Corp was incorporated in Delaware on September 8, 2011. It is a biotechnology company focused on discovering, developing and commercializing therapies based on its proprietary, next-generation RNA interference "RNAi" platform. The Company's proprietary therapeutic platform is comprised of novel RNAi compounds, referred to as rxRNA compounds, that are distinct from and it believes convey significant advantages over, conventional siRNA, and offers many of the properties that it believes are important to the clinical development of RNAi-based drugs. It has developed a number of forms of rxRNA compounds, all of which have been shown to be potent both in vitro and in preclinical in vivo models. These RNAi compounds include rxRNAori and sd-rxRNA, or self-delivering RNA. The Company's clinical product candidate is RXI-109, a self-delivering RNAi compound being developed for the reduction of dermal scarring. RXI-109 is designed to reduce the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in scarring and fibrotic diseases. RXI-109 is being developed to prevent or reduce dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids. The OPKO RNAi patents and patent applications encompass 12 patent families and includes 41 issued patents. The Company competes with Alnylam Pharmaceuticals, Inc., Marina Biotech, Inc., Tacere Therapeutics, Inc., Benitec Limited, Silence Therapeutics plc, Quark Pharmaceuticals, Inc., Rosetta Genomics Ltd., Lorus Therapeutics, Inc., Tekmira Pharmaceuticals Corporation, Arrowhead Research Corporation, Regulus Therapeutics Inc. and Santaris. The Company is subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and specific waste products. It is also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of bio-hazardous materials.
» More Articles for RXII

Headlines

Articles On GuruFocus.com
comment on RXII Mar 09 2013 
RXi Pharmaceuticals Corp. (RXII) CEO Noah D Beerman buys 10,000 Shares Jul 12 2010 
RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2009 Aug 14 2009 
CytRx Reports 2009 Second Quarter Financial Results Aug 10 2009 

More From Other Websites
RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's... Mar 27 2015
RXI PHARMACEUTICALS CORP Files SEC form 8-K, Other Events Mar 24 2015
RXi Pharmaceuticals Reports Positive Advancements in its Dermatology Programs at the Occasion of the... Mar 23 2015
RXi Pharmaceuticals to Webcast Fourth Quarter and Year End 2014 Financial Results on Monday, March... Mar 16 2015
RXi Pharmaceuticals to Present at the 73rd Annual Meeting of the American Academy of Dermatology Mar 11 2015
RXi Pharmaceuticals Announces Closing of the Exclusive Global Licensing Agreement to Samcyprone™... Feb 05 2015
RXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Ocular Indications Feb 03 2015
RXi Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference Feb 02 2015
Express Scripts facing antitrust, contract complaint Jan 14 2015
RXi Pharmaceuticals blames social media for recent stock slide Jan 05 2015
RXi Pharmaceuticals to Present at the 7th Annual Biotech Showcase™ Jan 05 2015
RXi Pharmaceuticals Issues Open Letter to Shareholders Dec 22 2014
RXI PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination... Dec 19 2014
RXi Pharmaceuticals Expands its Clinical Pipeline with an Exclusive Global License for a Second... Dec 19 2014
RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery... Dec 17 2014
Galena Biopharma to Present at the Oppenheimer 25th Annual Healthcare Conference Nov 25 2014
RXI PHARMACEUTICALS CORP Financials Nov 21 2014
Galena Biopharma Announces Purchase Agreement for Up to $55.0 Million With Lincoln Park Capital... Nov 20 2014
Galena Biopharma Completes Enrollment in GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical... Nov 18 2014
RXI PHARMACEUTICALS CORP Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 13 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK